Loading clinical trials...

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes

NCT05445232•Eli Lilly and Company

Summary

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)
•Male and female participants of childbearing potential who agree to use contraceptive methods

Exclusion Criteria

•Have a history of diabetes or current diagnosis of diabetes
•History or presence of a of significant bleeding disorder
•Participants with significant comorbidity
•Participants receiving treatment with midazolam, warfarin, inhibitors or inducers of cytochrome P450 (CYP) -1A2, CYP2C9, or CYP3A4 enzymes, or drugs are CYP substrates and have a narrow therapeutic index

Locations (2)

Covance Clinical Research Unit

Daytona Beach, Florida, United States

Covance Dallas

Dallas, Texas, United States

Key Dates

Start Date

July 8, 2022

Primary Completion Date

February 24, 2023

Completion Date

February 24, 2023

Last Updated

April 18, 2023

Enrollment

ACTUAL participants

Conditions

Obesity

Interventions

LY3437943

DRUG

Midazolam

DRUG

Warfarin

DRUG

Caffeine

DRUG

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Protein Supplementation Intervention on Body Weight

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss